Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference

CHICAGO 2026

Genitourinary Cancer

LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer

Genitourinary Cancer

Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy

Eur Urol

Briganti A, Steuber T, Shore ND, Gleave M, Kretschmer A, Wetherhold L, Efstathiou E, Cahn DJ, Damião R, De La Taille A, Byun SS, Hadaschik BA, Imbroda BH, Soto ÁJ, Merseburger AS, Simone G, Rooney B, Mikerin D, Li Z, Miladinovic B, McCarthy SA, Wildgust M, Mundle SD, Kibel AS, Taplin ME

doi: 10.1016/j.eururo.2026.10.016

Genitourinary Cancer

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Eur J Cancer

Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ

doi: 10.1016/j.ejca.2025.116110

Genitourinary Cancer

ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer

J Clin Oncol

Williams S, Sweeney CJ, Thomas H, Mak B, Zhang A, Lim TS, Jose C, Martin J, Patanjali N, Pryor D, Tran P, Mangar S, Mihai AM, Thomas C, Gampenrieder S, Yip S, Cheung L, Lee S, Goodwin A, Haworth A, Walsh A, Kelly PJ, Hughes S, Martin A, McDermott R, Stockler M, Davis ID, Nguyen PL

doi: 10.1200/JCO-26-01794

COMMENTED

Genitourinary Cancer

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Urol

Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ

doi: 10.1097/JU.0000000000004890

Genitourinary Cancer

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints

J Urol

Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EP, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ

doi: 10.1097/JU.0000000000004879

Genitourinary Cancer

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

N Engl J Med

Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS, PROTEUS Investigators

doi: 10.1056/NEJMoa2603878

Genitourinary Cancer

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer

BJU Int

Al-Nader M, Kesch C, Mahmoud O, Hadaschik BA, Fichtner J, Carl G, Feick G, Burchardt M, Zimmermanns V, Prause L, Polat B, Blana A, Horstmann M, Saar M, Miglierini P, Almansur K, Hefermehl L, Porres D, Peters I, Wiens K, Palisaar RJ, Winter A, Neisius A, Kunzmann EM, Harke NN, Bolenz C, Albarghouth MH, Manka L, Kramer M, Luger F, Knoll T, Pfitzenmaier J, Brock M, Schittko J, Sommer JP, Reichert M, Lenart S, Huber P, Hijazi S, Calderaro A, Hermanns T, Tonhauser J, Kowalski C, Sibert NT

doi: 10.1111/bju.70167

Genitourinary Cancer

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis

JAMA Oncol

Miszczyk M, Mastroleo F, Kujawska A, Gurwin A, Marvaso G, Kói T, Calleris G, Rasing M, Chin J, Fuller D, Nathan A, Peters M, van der Voort van Zyp J, Jenjitranant P, Hruby G, Soeterik TFW, Francolini G, Exterkate L, Overduin CG, Marra G, Gontero P, Alfarhan AR, Rajwa P, Kishan AU, Jereczek-Fossa BA, Shariat SF, DEFER-PC Collaborators

doi: 10.1001/jamaoncol.2026.1023

Related content

LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer

Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis